Glenmark Pharmaceuticals Ltd

NSE: GLENMARK · BSE: 532296 · Pharmaceuticals & Biotechnology · 39 announcements

Glenmark Pharmaceuticals Ltd news stories on ALFA NewsRead the news →

Share price: ₹2,282.30
Market cap: ₹64,412 Cr
Revenue (annual): ₹16,983 Cr
Net profit (annual): ₹1,362 Cr
P/E (TTM): 35.8×Sector 47.4×
Promoter holding: 46.65%+0.00% QoQ
FII holding: 20.89%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

11 Aug 2026 22:33 IST NSE

Glenmark Pharmaceuticals Legal & Regulatory

Glenmark Pharmaceuticals agreed to a $15.28 million settlement with Humana, Inc. to resolve antitrust litigation. This payment has been fully provided for in the company's financials.

Value: ₹145.3 Cr

Read the filing ↗

23 May 2026 09:26 IST NSE

Legal & Regulatory

Glenmark Pharmaceuticals Legal & Regulatory

Glenmark USA settled US antitrust litigation with state attorneys general for ₹281.47 Crore. Payable over five years, the settlement avoids uncertainty without admitting any liability.

Value: ₹281.5 Cr
Execution: 5 years

Read the filing ↗